Pharming Group N.V annual total liabilities
2019
2020
2021
2022
2023
2024
2025
Pharming Group N.V Total Liabilities Growth & History (PHAR)
Pharming Group N.V's total liabilities was $222.9M for fiscal 2025.
View full Pharming Group N.V company overviewPharming Group N.V annual total liabilities history
| Fiscal year | Period ended | Total liabilities | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $222.9M | $43.9M | +24.56% |
| 2024 | 2024-12-31 | $178.9M | −$65.1M | −26.69% |
| 2023 | 2023-12-31 | $244.1M | $22.9M | +10.36% |
| 2022 | 2022-12-31 | $221.2M | $16.8M | +8.20% |
| 2021 | 2021-12-31 | $204.4M | −$30.6M | −13.03% |
| 2020 | 2020-12-31 | $235.0M | $96.5M | +69.66% |
| 2019 | 2019-12-31 | $138.5M | — | — |
Pharming Group N.V quarterly total liabilities
Q4.20
Q4.21
Q4.22
Q4.23
Q4.24
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Total liabilities | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $197.5M | −$9.2M | −4.46% |
| Q1 2026 | 2026-03-31 | $220.4M | — | — |
| Q4 2025 | 2025-12-31 | $222.9M | $43.9M | +24.56% |
| Q3 2025 | 2025-09-30 | $209.1M | — | — |
| Q2 2025 | 2025-06-30 | $206.7M | — | — |
| Q4 2024 | 2024-12-31 | $178.9M | −$65.1M | −26.69% |
| Q4 2023 | 2023-12-31 | $244.1M | $22.9M | +10.36% |
| Q4 2022 | 2022-12-31 | $221.2M | $16.8M | +8.20% |
| Q4 2021 | 2021-12-31 | $204.4M | −$30.6M | −13.03% |
| Q4 2020 | 2020-12-31 | $235.0M | — | — |
Pharming Group N.V total liabilities trends
Over the last five fiscal years, Pharming Group N.V's total liabilities decreased from $235.0M to $222.9M, a change of −$12.2M. The latest reported quarter, Q2 2026, shows $197.5M.
About the metric
What total liabilities mean
Total liabilities are all obligations reported on a company’s balance sheet, including debt, accounts payable, accrued expenses, deferred revenue, lease liabilities, and other current and long-term obligations.
Calculation and source
SEC-reported and calculated total liabilities
TickerStat uses total liabilities reported in company SEC filings when available. Otherwise, it calculates total liabilities as aligned total assets minus total equity for the same balance-sheet date. Total liabilities should not be confused with interest-bearing debt. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Pharming Group N.V source filings ↗Community posts
Pharming expands Joenja approval to younger children with APDS
Pharming ($PHAR) secured FDA approval to use Joenja in children aged four to 11 with activated PI3K delta syndrome who weigh at least 27 kilograms. The expansion adds younger patients to the medicine’s existing indication for older patients ...